Concepts (89)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Veterans | 5 | 2025 | 1766 | 1.340 |
Why?
|
| Gulf War | 1 | 2025 | 10 | 0.920 |
Why?
|
| Persian Gulf Syndrome | 1 | 2025 | 16 | 0.910 |
Why?
|
| Pharmacogenomic Testing | 1 | 2024 | 45 | 0.890 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2024 | 34 | 0.880 |
Why?
|
| Suicidal Ideation | 1 | 2025 | 254 | 0.730 |
Why?
|
| Pre-Exposure Prophylaxis | 4 | 2024 | 53 | 0.640 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 471 | 0.630 |
Why?
|
| Depressive Disorder, Major | 1 | 2022 | 453 | 0.530 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2022 | 651 | 0.470 |
Why?
|
| Anti-HIV Agents | 3 | 2023 | 348 | 0.450 |
Why?
|
| HIV Infections | 4 | 2024 | 2050 | 0.330 |
Why?
|
| Substance-Related Disorders | 2 | 2024 | 491 | 0.300 |
Why?
|
| Tramadol | 1 | 2024 | 7 | 0.230 |
Why?
|
| Codeine | 1 | 2024 | 23 | 0.220 |
Why?
|
| Epigenomics | 1 | 2025 | 191 | 0.210 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2024 | 45 | 0.210 |
Why?
|
| Intimate Partner Violence | 1 | 2024 | 29 | 0.210 |
Why?
|
| Pharmacogenetics | 1 | 2024 | 200 | 0.200 |
Why?
|
| Depression | 2 | 2022 | 1350 | 0.200 |
Why?
|
| Afghanistan | 1 | 2022 | 16 | 0.200 |
Why?
|
| Iraq | 1 | 2022 | 11 | 0.200 |
Why?
|
| Drug Prescriptions | 1 | 2024 | 239 | 0.190 |
Why?
|
| United States | 4 | 2025 | 11675 | 0.190 |
Why?
|
| Pain | 1 | 2024 | 462 | 0.180 |
Why?
|
| Counselors | 1 | 2021 | 24 | 0.170 |
Why?
|
| Schizophrenia | 1 | 2024 | 332 | 0.170 |
Why?
|
| Patient Navigation | 1 | 2021 | 27 | 0.170 |
Why?
|
| Text Messaging | 1 | 2021 | 40 | 0.170 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2024 | 697 | 0.170 |
Why?
|
| Police | 1 | 2020 | 14 | 0.170 |
Why?
|
| Liraglutide | 1 | 2020 | 15 | 0.160 |
Why?
|
| Appetite Depressants | 1 | 2020 | 23 | 0.160 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2020 | 40 | 0.160 |
Why?
|
| Surveys and Questionnaires | 3 | 2025 | 3995 | 0.160 |
Why?
|
| Nurses | 1 | 2020 | 74 | 0.160 |
Why?
|
| GABAergic Neurons | 1 | 2020 | 64 | 0.160 |
Why?
|
| Islet Amyloid Polypeptide | 1 | 2019 | 13 | 0.160 |
Why?
|
| Health Personnel | 1 | 2024 | 545 | 0.160 |
Why?
|
| Calcitonin | 1 | 2019 | 32 | 0.150 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2019 | 74 | 0.150 |
Why?
|
| Genome-Wide Association Study | 2 | 2024 | 1831 | 0.150 |
Why?
|
| Genotype | 1 | 2024 | 2703 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2024 | 767 | 0.140 |
Why?
|
| Humans | 11 | 2025 | 132257 | 0.130 |
Why?
|
| Middle Aged | 3 | 2025 | 29027 | 0.120 |
Why?
|
| Adult | 4 | 2025 | 31620 | 0.120 |
Why?
|
| Biomarkers | 1 | 2025 | 3404 | 0.120 |
Why?
|
| Anxiety Disorders | 1 | 2021 | 734 | 0.120 |
Why?
|
| Weight Loss | 1 | 2019 | 515 | 0.120 |
Why?
|
| Anxiety | 1 | 2021 | 1001 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 899 | 0.110 |
Why?
|
| Female | 7 | 2025 | 70792 | 0.110 |
Why?
|
| Male | 6 | 2025 | 65019 | 0.100 |
Why?
|
| Intention | 2 | 2024 | 100 | 0.100 |
Why?
|
| Young Adult | 1 | 2025 | 9970 | 0.080 |
Why?
|
| Risk Factors | 1 | 2022 | 10946 | 0.070 |
Why?
|
| Obesity | 1 | 2019 | 2398 | 0.070 |
Why?
|
| Eating | 2 | 2020 | 381 | 0.070 |
Why?
|
| Sexual Partners | 1 | 2024 | 85 | 0.050 |
Why?
|
| Rats | 2 | 2020 | 3607 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2025 | 234 | 0.050 |
Why?
|
| Sexual Behavior | 1 | 2024 | 250 | 0.050 |
Why?
|
| Perception | 1 | 2023 | 236 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2025 | 662 | 0.040 |
Why?
|
| Philadelphia | 1 | 2021 | 27 | 0.040 |
Why?
|
| Counseling | 1 | 2023 | 233 | 0.040 |
Why?
|
| New York City | 1 | 2021 | 65 | 0.040 |
Why?
|
| Solitary Nucleus | 1 | 2020 | 4 | 0.040 |
Why?
|
| Program Development | 1 | 2021 | 191 | 0.040 |
Why?
|
| Health Facilities | 1 | 2020 | 69 | 0.040 |
Why?
|
| Violence | 1 | 2020 | 127 | 0.040 |
Why?
|
| Receptors, Glucagon | 1 | 2019 | 31 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2021 | 425 | 0.040 |
Why?
|
| Anti-Obesity Agents | 1 | 2019 | 44 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2021 | 456 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2023 | 1444 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2020 | 774 | 0.040 |
Why?
|
| Cognition | 1 | 2023 | 811 | 0.030 |
Why?
|
| Diet, High-Fat | 1 | 2019 | 255 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2020 | 1224 | 0.030 |
Why?
|
| Energy Intake | 1 | 2019 | 493 | 0.030 |
Why?
|
| Body Weight | 1 | 2019 | 995 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2019 | 1121 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2024 | 5176 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 697 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2019 | 784 | 0.030 |
Why?
|
| Animals | 2 | 2020 | 34850 | 0.020 |
Why?
|
| Aged | 1 | 2024 | 21484 | 0.010 |
Why?
|